Xtant Medical Holdings, Inc. Announces Executive Changes
July 10, 2018 at 06:40 am EDT
Share
On July 9, 2018, Xtant Medical Holdings, Inc. terminated the employment of Chris Valois, who served as Vice President, Sales and Marketing of the company, effective immediately. To succeed Mr. Valois, the company appointed Kevin D. Brandt as Senior Vice President of the company, effective immediately. Mr. Brandt brings to the Company more than 28 years of experience in the medical device industry. As the former Executive Vice President and Chief Commercial Officer of RTI Surgical, Inc. Prior to joining RTI Surgical in 2012, Mr. Brandt was the president of Osteokinetics from 2002-2012, and from 2000-2001 he was a senior director for U.S. spine sales at Stryker.
Xtant Medical Holdings, Inc. is a global medical technology company. The Company is focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. Its biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, and its line of 3Demin products, as well as other allografts. It offers a comprehensive line of products that are used to treat a variety of spinal and sacroiliac conditions, including trauma, degeneration, deformity and tumor. Its key spinal implant product lines include Cervical Products, Thoracolumbar Products, Sacroiliac Joint Products, Interbody Products and Interlaminar Stabilization Products.
XTANT MEDICAL HOLDINGS, INC. 
